Stockreport

Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming [Yahoo! Finance]

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com
PDF and will report two–three additional cohorts later this month while running phase 1b studies in severe atopic dermatitis and asthma with a phase 2b asthma study planned [Read more]